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ABSTRACT 49 
Background: Epidemiological evidence suggests a diet rich in (poly)phenols has beneficial 50 
effects on many chronic diseases. Brown seaweed is a rich source of (poly)phenols 51 
Objective: The aim of this study was to investigate the bioavailability and effect of a brown 52 
seaweed (Ascophyllum nodosum) (poly)phenol extract from on DNA damage, oxidative stress, 53 
and inflammation in vivo. 54 
Design: A randomised double-blind placebo-controlled crossover trial was conducted in 80 55 
participants aged 30-65 years with a BMI ≥25kg/m2. The participants consumed either a 400 56 
mg capsule containing 100 mg of seaweed (poly)phenol and 300 mg maltodextrin or a 400 mg 57 
maltodextrin placebo control capsule daily for an 8-week period.  Bioactivity was assessed 58 
with a panel of blood-based markers including lymphocyte DNA damage, plasma oxidant 59 
capacity, C-reactive protein and inflammatory cytokines. To explore the bioavailability of 60 
seaweed phenolics, an untargeted metabolomics analysis of urine and plasma samples 61 
following seaweed consumption was determined by UHPLC-HR-MS.  62 
Results: Consumption of the seaweed (poly)phenols resulted in a modest decrease DNA 63 
damage but only in a subset of the total population who were obese. There were no significant 64 
changes in CRP, antioxidant status, inflammatory cytokines. We identified phlorotannin 65 
metabolites that are considered potential biomarkers of seaweed consumption including 66 
pyrogallol/phloroglucinol-sulfate, hydroxytrifurahol A-glucuronide, dioxinodehydroeckol-67 
glucuronide, diphlorethol sulfates, C-O-C dimers of phloroglucinol sulfate, C-O-C dimers of 68 
phloroglucinol and diphlorethol sulfate.  69 
Conclusion: To the best of our knowledge, this work represents the first comprehensive 70 
study investigating the bioactivity and bioavailability of seaweed (poly)phenolics in human 71 
participants. We identified several potential biomarkers of seaweed consumption. Intriguingly, 72 
the modest improvements in DNA damage were observed only in the obese subset of the total 73 
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population, the subgroup analysis should be considered exploratory as it was not preplanned; 74 
therefore, are not powered adequately. Elucidation of the biology underpinning this observation 75 
will require participant stratification according to weight in future studies. 76 
 77 
Key words: Seaweed, Phenolic compounds, Inflammation, DNA damage, Oxidative stress, 78 
bioavailability 79 
80 
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INTRODUCTION 81 
Diets rich in plant-derived foods may reduce risk of chronic degenerative diseases, including 82 
cardiovascular disease (CVD), with the beneficial effects being attributable in part to highly 83 
bioactive (poly)phenolic compounds contained therein (1-3). Fruits and vegetables are well-84 
known sources of (poly)phenols, but a less well-known source is Ascophyllum nodosum, a 85 
brown algae common to the British Isles that is rich in (poly)phenolic compounds, including, 86 
uniquely, phlorotannin (4, 5). Phlorotannins are oligomers of phloroglucinol whose 87 
concentration in seaweed is affected by numerous factors including plant size and age, water 88 
salinity, nutrient and heavy metal content, in addition to light intensity changes (6-8). 89 
Ascophyllum nodosum is of interest as it is one of only a few commercially sustainable seaweed 90 
species. 91 
Phlorotannins – and brown seaweed extracts in general – exhibit beneficial effects on a 92 
range of biological processes including modulation of inflammation, reduction of oxidative 93 
stress and improvements in cardiovascular function (9-11). However, the evidence base relies 94 
heavily on cell line and small animal models, with few studies to date involving humans (12-95 
13). Phlorotannin-rich extracts from brown seaweeds have been shown to be effective in 96 
controlling inflammation via a number of pathways including inhibition of pro-inflammatory 97 
cytokines including tumour necrosis factor (TNF)-α and interleukins (IL)-1β and IL-6 in vitro 98 
(14). The efficacy of Ascophyllum nodosum and other Fucoid species extracts in mitigating the 99 
effects of oxidative stress by inhibiting the generation of reactive oxygen species (ROS), 100 
preventing DNA damage and in stimulating the production of glutathione in affected cells has 101 
been demonstrated in our work and that of other researchers (15-20).  Our  initial in vitro (15) 102 
and acute in vivo (20) observations of the antioxidant and anti-inflammatory activities of 103 
Ascophyllum nodosum extract(s) gave rise to the hypothesis that longer term consumption of 104 
Ascophyllum nodosum-derived (poly)phenols would be of benefit in vivo. 105 
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A few investigations have evaluated – either in vitro or in vivo – the bioactivity of 106 
phlorotannin rich extracts from Fucoid species. For example, safe consumption levels for a 107 
(poly)phenol-enriched extract of the brown seaweeds Ascophyllum nodosum and Fucus 108 
vesiculosus and its effects on glycaemic response have been determined in clinical trials (21). 109 
To the best of our knowledge, we now report the first clinical study aimed at specifically 110 
addressing the effects of a phlorotannin-rich extract from Ascophyllum nodosum on oxidative 111 
damage to DNA, plasma antioxidant capacity, inflammatory responses and chronic, low level 112 
inflammation in vivo. 113 
 114 
PARTICIPANTS AND METHODS 115 
Seaweed material  116 
Fresh Ascophyllum nodosum was supplied by The Hebridean Seaweed Company, Isle of Lewis, 117 
Scotland, UK, in March 2011. The seaweed biomass was harvested by hand to ensure quality, 118 
cleaned of contaminating sand and fouling organisms and then shipped refrigerated to the 119 
processing facility (CEVA) in France where it was immediately chopped and frozen. 120 
 121 
Preparation of food-grade seaweed extracts and capsule   122 
A (poly)phenol-rich seaweed extract from Ascophyllum nodosum was produced by CEVA 123 
(France) using a food–grade solvent (ethanol:water, 60:40 vol/vol) extraction system that was 124 
specifically developed for use with fresh or frozen Ascophyllum nodosum. Approximately half 125 
of the produced extract was then fractionated using tangential flow ultra-filtration to produce 126 
further extracts of varying molecular weight ranges and with varying (poly)phenol content. A 127 
standardised blended (poly)phenol-rich Ascophyllum nodosum extract was formulated by 128 
CEVA (Table 1) using 175 mg of extract and 50 mg of high molecular weight fraction (>10 129 
kDa cut off) for use in the current study, in order to maximise the seaweed (poly)phenol content 130 
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(>100 mg per day) available from the extraction of fresh or frozen Ascophyllum nodosum 131 
against the need to minimise the level of iodine to within accepted regulatory guidelines (<500 132 
μg per day) (Table 1), heavy metal contamination was also assessed. Maltodextrin (175 mg) 133 
was added to the capsule formulation as an excipient. Blending was carried out at the food–134 
grade CEVA facilities in France. Samples of 400 mg of the Ascophyllum (poly)phenol–rich 135 
blend (SPE) or a placebo containing 400 mg maltodextrin only were packed into identical 136 
white, opaque, vegetarian capsules by Irish Seaweeds, Belfast, UK and identically sized and 137 
matched capsules were used for the clinical study. The food–grade seaweed capsule was 138 
characterized by NP-HPLC and LC-MS analysis and is reported elsewhere (20) (see 139 
Supplemental figures 1 & 2). Phlorotannins were quantified using the Folin-Ciocalteau 140 
Method (22) using phloroglucinol as the standard. In brief, 1 mL of suitability diluted sample 141 
was reacted with 1 mL of 40 % Folin Ciocalteu reagent for 5 min, and then made alkaline with 142 
the addition of 1 mL of 100 g/L Na2CO3. Absorbance was read at 730 nm after the solution 143 
had developed for 1 h at room temperature. Phloroglucinol dihydrate (range 0-30 mg/L) was 144 
used as a standard and was treated in the same way as samples. 145 
 146 
Ethics and participants 147 
Ethical approval was received from the Ulster University Research Ethics Committee 148 
(UUREC). All participants gave written informed consent. Participants were recruited between 149 
May 2011 and August 2011 from Ulster University and the surrounding area. The intervention 150 
study ran between August 2011 and February 2012. The study was registered at 151 
clinicaltrials.gov as NCT02295878.  152 
The study was conducted in 80 participants (age range 30-65 years). All participants were 153 
apparently healthy, non-smoking, BMI≥25 kg/m2, omnivores, who did not habitually use 154 
vitamin or mineral supplements, as determined using a pre-screening health and lifestyle 155 
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questionnaire. Pregnant and lactating women, vegetarians and vegans and lactose–intolerant 156 
individuals were excluded from the study, as were those with chronic medical complications 157 
such as diabetes, cardiovascular disease, autoimmune/inflammatory disorders, or who had 158 
chronic medication use including anti-inflammatory agents.  159 
 160 
Study design 161 
The study was a 24-week randomised, double-blind, placebo-controlled crossover trial. 162 
After obtaining consent, participants were randomly assigned, in blocks of four using a 163 
random-number generator (www.randomization.com), to either the intervention or the control. 164 
In total, eighty participants were randomised to 2 groups of 40, each starting on either a 400 165 
mg seaweed (poly)phenol  extract (SPE) capsule containing 100mg of (poly)phenols or a 400 166 
mg maltodextrin placebo control capsule (Avebe MD14P) daily for an 8-week period. The 167 
participants were supplied with all capsules in weekly labelled capsule boxes at the beginning 168 
of each phase, which was interspersed by an 8-week washout phase. During the washout phase, 169 
the participants were asked to maintain their habitual diet. Participants were asked to bring any 170 
unconsumed capsules to their study appointment at the end of each treatment phase and were 171 
also contacted weekly by the study researcher to encourage compliance and to discuss any 172 
difficulties they were experiencing.  173 
 174 
Blood and urine sample collection 175 
Fasting blood samples were collected before and after each phase (week 0, week 8, week 176 
16, and week 24) by venepuncture into EDTA, serum or sodium heparin-containing tubes, as 177 
required. All blood samples were processed on ice. Lymphocytes were isolated by using 178 
Histopaque-1077, according to the manufacturer’s instructions (Sigma Diagnostics, St Louis, 179 
MO), and plasma samples were prepared by centrifugation at 1000 × g for 10 min at 4 °C. 180 
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Serum samples were allowed to clot for 30 min at room temperature and then were centrifuged 181 
at 2000 × g for 10 min at 4 °C. Whole blood from sodium-heparin treated tubes was prepared 182 
according to the manufacturer’s instructions (BD Bioscience Fast Immune Cytokine System). 183 
Whole blood, plasma, serum and urine samples were immediately stored at -80 °C, whereas 184 
lymphocytes were stored frozen in liquid nitrogen. All biological measurements were carried 185 
out at the end of the intervention in batches containing equal numbers of active and control 186 
phase samples in each batch, and the researchers were blinded to these samples during analyses. 187 
A 24 h urine collection occurred at each time point; volume and pH were measured and the 188 
sample mixed following which 2 × 14ml aliquots were removed and centrifuged at 1000 x g 189 
for 10 min at 4 °C. Supernatants were stored at -80 °C until required. 190 
 191 
Questionnaire assessments 192 
All participants completed a health and lifestyle questionnaire assessing their alcohol intake 193 
and physical activity levels, as well as a validated 4-day food diary at the mid-point during 194 
each treatment phase (active/placebo) of the study. Data on type of food and corresponding 195 
weight was entered into a food analysis database (WISP, Weighed Intake Software Program; 196 
Tinuviel Software, Warrington, U.K.) by two independent researchers and the dietary 197 
composition calculated.  198 
 199 
DNA damage in peripheral blood mononuclear cells 200 
Peripheral blood lymphocytes, previously isolated and stored in liquid nitrogen, were 201 
thawed and screened for basal single strand breaks (SBs) in DNA using the single cell gel 202 
electrophoresis (Comet) assay (23) as adapted by Gill et al. (24). Spontaneous DNA SBs are 203 
associated with an altered cell function and are considered appropriate for the substantiation of 204 
health claims in the context of protection against generic DNA damage (25). In addition, 205 
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resistance to induced DNA damage (SB) was measured in lymphocytes subjected to increased 206 
oxidative insult ex vivo by pre-treating lymphocytes with 150 µmol H2O2/L for 5 min at 4°C, 207 
before the measurement of SBs. The mean (percentage DNA in tail) was calculated from 50 208 
cells per gel (each sample in triplicate) and the mean of each dataset was used in the statistical 209 
analysis. 210 
 211 
Plasma total oxidative capacity 212 
Total oxidative capacity (TOC) measures total peroxide levels in plasma, by the reaction of 213 
endogenous peroxides with peroxidases, using tetramethylbenzidine (TMB) as the 214 
chromogenic substrate (26) with spectrophotometric measurement at 450 nm. To 10 μL of 215 
standard (freshly-prepared hydrogen peroxide, 0.1 mmol/L) or samples in an uncoated 216 
microtiter plate was added 200 μL of reaction mixture (0.05M phosphate-citrate buffer, pH 5.0; 217 
TMB solution (1 mg/mL), and peroxidase (>2500U/mL) in a proportion of 100:10:1. Plates 218 
were incubated at room temperature for 15 min, following which 50 μL of stop solution (2M 219 
H2SO4) was added to all wells and absorbance at 450 nm was measured using a microplate 220 
reader (GENIOS Tecan). Hydrogen peroxide standard solutions (range 0 - 1 mmol/L) were 221 
freshly prepared before use. 222 
 223 
Lipid profile and serum C-reactive protein  224 
Plasma total cholesterol, HDL cholesterol and triglycerides were measured on an Instrument 225 
Laboratory (ILAB) 600 (Warrington, UK) autoanalyzer using commercial kits (Roche 226 
diagnostics, Lewis, UK) according to kit manufacturer’s protocols. Plasma LDL cholesterol 227 
was calculated using the Friedewald formula (27). 228 
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C-reactive protein was determined on an ILAB 600 autoanalyser using a Quantex CRP 229 
Ultra-Sensitive commercial kit (0.4-18.3 µg/dL) in accordance with the manufacturer’s 230 
instructions. 231 
 232 
Measurement of inflammatory markers 233 
Intracellular cytokine levels in lymphocyte and monocyte populations and tissue factor (TF) 234 
expression were assessed using a whole blood labelling method that utilises flow-cytometry 235 
(Fast Immune Cytokine System, BD Biosciences) in accordance with manufacturer’s 236 
instructions for all participants at all time-points. The method was used to measure intracellular 237 
IL-1β, IL-2, IL-6, IL-10, IL-12, interferon (IFN)-γ and tumour necrosis factor (TNF)-α 238 
expression in mononuclear cells. Briefly, whole blood was incubated with either 239 
lipopolysaccharide or phorbol 12-myristate 13-acetate to activate monocytes and lymphocytes, 240 
respectively. Cells were labelled with the appropriate cell surface antibody and cytokine-241 
specific antibody and analysed on a Gallios flow cytometer (Beckman Coulter). The number 242 
and percentage of each cell type expressing the cytokine, as well as the mean channel 243 
fluorescence was recorded. The cytokine profiles were examined by ratio of TNF-α to IL-10, 244 
IL-1β to IL-10, IL-6 to IL-10 and CRP to IL-10, according to Laird et al. (29).  245 
 246 
Extraction of (poly)phenols from urine and blood samples. 247 
 Urine samples were defrosted, vortexed, centrifuged at 16,110 × g for 10 min at 5 °C, and 248 
passed through 0.45 μm filter discs prior to the analysis of 50 μL aliquots by UHPLC-HR-MS. 249 
The extraction of metabolites from the plasma samples was carried out as described previously 250 
(28). Briefly, plasma samples were defrosted, vortexed and 400 µL aliquots mixed with 10 µL 251 
of ascorbic acid (10%, v/v), and 980 µL of 1% formic acid in acetonitrile. One µg of rutin was 252 
added to the samples as internal standard for plasma extraction efficiency. The samples were 253 
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then vortexed for 1 min and ultrasonicated for 10 min. After centrifugation at 16,110 g for 15 254 
min, supernatants were reduced to dryness in vacuo using a concentrator plus (Eppendorf, 255 
Hamburg, Germany) and resuspended in 150 µL of distilled water containing 1% formic acid 256 
and 50 µL of methanol, which was then centrifuged at 16,110 g for 10 min. Analysis of 10 μL 257 
aliquots of the supernatant was by UHPLC-HR-MS. Recovery of the internal standard was 79 258 
± 16% (n=78). 259 
 260 
Non-targeted analysis of urine and plasma by UHPLC-HR-MS.  261 
Plasma and urine samples were analysed using a Dionex Ultimate 3000 RP UHPLC system 262 
comprising of a UHPLC pump, a PDA detector scanning from 200 to 600 nm, and an 263 
autosampler operating at 4 °C (Thermo Scientific). The HPLC conditions were previously 264 
described by Corona et al., (20) with some modifications. Briefly, reverse phase separations 265 
were carried out using a 100 x 2.1 mm i.d. 1.8 µm Zorbax SB C18 (Agilent) maintained at 25 266 
°C and eluted at a flow rate of 0.2 mL/min with a 50 min gradient of 3-70% of 0.1% acidic 267 
methanol in 0.1% aqueous formic acid. After passing through the flow cell of the PDA detector 268 
the column eluate was directed to an ExactiveTM Orbitrap mass spectrometer fitted with a 269 
heated electrospray ionization probe (Thermo Scientific) operating in negative ionization 270 
mode. Analyses were based on scanning from 100 to 1000 m/z, with in-source collision-271 
induced dissociation at 25.0 eV. The capillary temperature was 350 °C, the heater temperature 272 
was 150 °C, the sheath gas and the auxillary gas flow rate were both 25 and 5 units, 273 
respectively, and the sweep gas was 4 and the spray voltage was 3.00 kv. Data acquisition and 274 
processing were carried out using Xcalibur 3.0 software. 275 
Untargeted analysis of the selected urine and plasma samples was performed using mass 276 
spectral data from the orbitrap analysis applied to the Compound Discoverer software (version 277 
2, Thermo Fisher Scientific Inc.). The Compound Discover application processes the raw data 278 
13 
 
 
into workflows that can be defined on the basis of the nature of the experimental setup. In our 279 
case, the workflow selected was 'untargeted metabolomics workflow' that includes retention 280 
time alignment, component detection, grouping, elemental composition prediction, gap filling, 281 
hide chemical background (using blanks), ID using mzCloud and ChemSpider and differential 282 
analysis. The parameters were adjusted to our experimental conditions. Samples were grouped 283 
and labelled according to our experimental design, either before or after supplementation of 284 
seaweed capsule, the output, as peak areas for the detected peaks was used to develop a 285 
multivariate data analysis by Orthogonal Partial Least Square Discriminant Analysis (OPLS-286 
DA). Analysis of seaweed phenolics in blood and urine was also undertaken by HPLC-DAD 287 
analysis (Supplemental Tables 1 & 2) in a manner consistent with previous studies (15, 20). 288 
 289 
Power calculations and statistical analyses 290 
Power calculations were performed for the primary endpoint of the change in DNA damage 291 
in peripheral blood mononuclear cells. Based on data from a previous study (24), 72.6 292 
participants were needed to detect a 25% change in DNA damage in lymphocytes (α 0.05).   293 
All values are expressed as mean ± SD, unless otherwise specified. The mean values are 294 
reported for all participants (n=78) during both treatment phases (SPE, Maltodextrin). 295 
Significant associations between several outcomes and confounders including BMI and gender 296 
were identified at baseline using bivariate correlations or independent t-tests, as appropriate 297 
(TOC & Gender P=0.03, DNA damage & BMI P=0.048, DNA damage & Gender P=0.009). 298 
Consequently, data was also analysed by stratification of increasing risk, including overweight 299 
participants (n=42) and obese participants (n=36). The subgroup analysis was not preplanned; 300 
therefore, are not powered adequately and should be considered exploratory. All biochemical 301 
analysis was conducted in duplicates, unless otherwise stated, and the mean values taken as the 302 
final result. For all markers, the results are presented as treatment effects. This was undertaken 303 
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by calculating individual differences between pre– and post– values for both control and 304 
treatment phases for each subject. Paired T-tests were then carried out on the difference scores 305 
(post-treatment value minus pre-treatment values) for both treatment phases (SPE and 306 
Maltodextrin). Significance level was set at P<0.05. All statistical analyses were performed 307 
using the Statistical Package for the Social Sciences (SPSS) for Windows version 22.0 (SPSS 308 
Inc., Chicago, IL, USA). 309 
 310 
Multivariate Data Analysis 311 
Data were obtained as peak areas from the Compound Discover automatic integration software 312 
and consisted of 2194 and 3289 potential metabolites (or features) in urine and plasma samples, 313 
respectively. Relative peak areas of the metabolites (normalized by the total urine excretion of 314 
each subject) obtained by UPLC-HRMS were imported into MATLAB R2015b (Mathworks, 315 
USA). PLS toolbox v.8.5 (Eigenvector, USA) and homemade scripts were used. Principal 316 
component analysis (PCA) and hierarchical cluster analysis (HCA) are the most widely used 317 
tools to explore similarities and patterns among samples where data grouping are unclear. 318 
Moreover, the orthogonal partial least squares discriminate analysis (OPLS-DA) method was 319 
performed as a typical supervised multivariate methodology used in metabolomics studies (30, 320 
31). Several data pre-processing transformations were performed and evaluated, such as 321 
Probabilistic Quote Normalization (PQN), Log transformation, mean centering, pareto scaling 322 
and auto-scaling. In our case, PQN and autoscaling were selected as pre-processing techniques 323 
to reach the lowest root mean square error (RMSE) in an iterative process. A re-sampling 324 
method, cross-validation k-fold cross validation (k=5) was also used to evaluate the number of 325 
latent variables (according to the lowest RMSE) and the prediction ability of our models. To 326 
reduce the impact of the random split of CV-participants, the mean values of the estimated 327 
results were obtained after 20 random 5-fold CV. Urine models provided successful 328 
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classification results at the cross validation step and achieved good prediction parameters that 329 
can be explained by the area under the curve values (1.00 and 0.895). Based on the plasma data 330 
set and classes selected a discriminant model could not be developed. Moreover, the Variable 331 
Importance in Projection (VIP) is the widely known metric that is used to identify potential 332 
markers in metabolomics studies (32). VIP is a weighted sum of squares of the PLS weight 333 
which indicates the importance of the variable to the whole model. The cut off VIP value 334 
selected in our study was 2. The potential markers were extracted from the two models to 335 
compare the results obtained.  336 
 337 
RESULTS 338 
Baseline characteristics 339 
Eighty participants (males n=39, females n=41) were enrolled on this 24-week randomised, 340 
double-blind, placebo-controlled crossover trial. The intervention was conducted as per the 341 
protocol and there were no adverse events associated with the intervention. The study 342 
population had a mean group age of 42.7±7.1 years and a mean BMI of 30.2±3.9 kg/m2. The 343 
study had an overall compliance of 97% with 78 participants completing the 24-week study; 344 
two participants withdrew from the study at the midpoint for personal reasons and compliance 345 
was not significantly different by treatment group or time period (P>0.05) (Figure 1). There 346 
were no significant differences between the participants in age and physical characteristics at 347 
the beginning of either treatment phase (Table 2). 348 
 349 
Habitual dietary intake  350 
Dietary analysis of habitual intake (midpoint) during both treatment phases (SPE, 351 
Maltodextrin) of the crossover trial is described in Table 3. There were no significant 352 
differences between treatment phases for any of the macronutrients or micronutrients analysed 353 
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indicating that the seaweed phenolic extract did not affect the habitual food consumption 354 
patterns in the study population. 355 
 356 
Effects of seaweed (poly)phenol  extract on DNA damage  357 
Basal levels of DNA damage observed in the study were consistent with previous studies 358 
with a mean group average of 6.72 ± 2.48% tail DNA (data not shown). In response to an 359 
oxidative challenge with 150 µM H2O2, DNA damage was increased to an average of 360 
approximately 34 ± 7% tail DNA in both the placebo and SPE phase in all participants (Table 361 
4). The 8-week intervention with a seaweed phenolic extract resulted in a significant reduction 362 
in basal DNA damage, as measured by the Comet assay, in obese participants only (BMI >30 363 
kg/m2), with a significant reduction (P=0.044) in basal DNA damage observed (Table 4). A 364 
significant reduction was not observed in the total population (n=78) nor in participants 365 
classified as overweight (n=42), either in terms of a challenge response or in basal levels.  In 366 
addition, we noted that consumption of seaweed phenolic extract also significantly reduced 367 
(P=0.009) basal DNA damage in males only with a mean group change value of  -0.8 ± 2.5 % 368 
tail DNA (SPE) compared to 0.9 ±2.8% tail DNA in the control. No significant effects were 369 
observed for females.  370 
 371 
Total oxidative capacity of seaweed phenolics 372 
Total oxidative capacity (peroxide levels) in plasma samples from all participants (n=78), 373 
in overweight participants (n=42) and in obese participants (n=36) were measured after the 374 
placebo and seaweed capsule intervention (Figure 2). There were no significant changes from 375 
baseline after either treatment phase (SPE, Maltodextrin) in all participants (n=78) nor in 376 
overweight (n=42) or obese (n=36) sub groups. However consumption of seaweed phenolic 377 
extract also significantly reduced (P=0.018) TOC in females only with a mean group change 378 
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value of  -7.44 ± 29.37 µM peroxides (SPE) compared to 4.33 ± 22.36 µM peroxides in the 379 
control. No significant effects were observed for males. 380 
 381 
Effects of seaweed (poly)phenol  extract on blood lipids and CRP 382 
Analysis of Pre- and post- values, and the percentage change, for both the placebo phase 383 
and the SPE phase for each blood lipid biomarker and CRP indicated that the 8-week 384 
supplementation with seaweed (poly)phenol extract did not significantly affect any 385 
cardiovascular risk marker (Table 4). 386 
 387 
Effects of seaweed (poly)phenol  extract on inflammatory markers 388 
No significant differences were measured in any of the inflammatory cytokines in either 389 
treatment phase (SPE, Maltodextrin) for all study participants (n=78) (Figure 4) and in addition 390 
no significant effects on the cytokine profiles were observed.   391 
 392 
Bioavailability of seaweed phenolics, untargeted analysis 393 
Initially an unsupervised PCA model was carried out (Figure 4A) on the urine data from all 394 
78 participants. The first component of the PC1 vs PC2 scores plot obtained from the data set 395 
explained 23.14% of the total variance showing a clear trend among some of the participants 396 
compared to the rest. Moreover, a hierarchical cluster analysis was performed to verify this 397 
natural aggrupation pattern among the 78 participants suggesting, two distinct clusters among 398 
all the participants (Figure 4B), accounting for the inter-individual differences associated with 399 
variation in the urinary metabolite profiles. Recent studies suggest that individuals can be 400 
clustered into distinct groups based on their gut microbiome composition, functional 401 
metabolism (33) or individual responses to obtain markers of a specific treatment, minimizing 402 
the inter-individual data that are not the target of the study. In order to elucidate the observed 403 
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variability between these two groups, two supervised models were performed, one with the 404 
urinary profiles from all the participants before the seaweed consumption and another one with 405 
the urinary profiles from all the participants after seaweed consumption. Both supervised 406 
models verified differences between the two groups of individuals (Group 1 and Group 2) and 407 
provided successful classification results at the cross validation step and achieved in the pre-408 
treatment and post-treatment samples 95% and 98% sensitivity (participants of the class of 409 
interest correctly assigned to their class) and 100% and 100% specificity (participants not 410 
belonging to the class of interest were correctly not assigned to that class), respectively 411 
(Supplemental Figure 3). It is noteworthy that even stratifying for BMI category, the 412 
multivariate analysis of the urine profiles did not show clear differentiation of the metabolome 413 
between obese or overweight individuals. 414 
By using the preliminary information provided by PCA and HCA related to the stratification 415 
of the individuals into groups which share a common excretion profile before and after 416 
supplementation with seaweed capsules, two data sets were analysed. The individuals were 417 
stratified into two groups; Group 1 including 70 participants; and Group 2 including 8 418 
participants (S58, S60, S61, S71, S76, S78, S79, S83, all being overweight individuals). Two 419 
supervised OPLS-DA models were built to discriminate according to the seaweed treatment in 420 
both models (Figure 5). In our study we used two latent variables (LV) and the sensitivity and 421 
specificity values were set to 100% at the calibration step recognition ability of the two models. 422 
These analyses showed that the human urine metabolome in both groups of participants was 423 
modified after the 8-week supplementation with seaweed (poly)phenol extract compared to 424 
baseline urine metabolic profiles. Using the loadings plot and the variable importance in 425 
projection values (VIP) we ascertained important contributors between the modelled classes 426 
and therefore identified the compounds responsible for the difference in the urine metabolic 427 
profile before and after 8-weeks seaweed (poly)phenol  extract consumption in both groups. 428 
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VIP is the widely known metric that is used to identify potential markers (metabolites) in 429 
metabolomics studies. Further, the urine scores plot allowed the identification of those 430 
metabolites which appeared after the seaweed (poly)phenol  extract intake (Figure 5) in both 431 
groups of participants.  432 
 433 
The main contributors to metabolome differentiation in the urine before and after seaweed 434 
consumption in both groups of participants are described in Supplemental Tables 3 & 4. 435 
Positive loading values (x axis) and higher VIP values (VIP>2.0) were detected  in urine after 436 
seaweed consumption and were the responsible of the observed differences between the 437 
participants classes (post ingestion vs non ingestion of seaweed (poly)phenol  extract). Urine 438 
metabolites tentatively identified as pyrogallol/phloroglucinol sulfate, hydroxytrifurahol A-439 
glucuronide and dioxinodehydroeckol glucuronide are considered clear biomarkers of seaweed 440 
consumption in Group 1 while C-O-C dimer of phloroglucinol-sulfate, C-O-C-dimer of 441 
phloroglucinol, fucophloroethol-glucuronide, diphlorethol sulfates and dioxinodehydroeckol 442 
glucuronide are those biomarkers of seaweed consumption in Group 2. All of them have shown 443 
high values in the variable importance in the projection (values > 2) (Table 5). 444 
Based upon the identified seaweed (poly)phenol metabolites, the total amount of seaweed 445 
metabolites excreted in urine varied noticeably between participant ranging from 0.001 to 446 
4.140 m moles, with a group average of 1.29 +/- 0.88 m moles.  Some 25% of the population 447 
(19/78) appeared to be low excretors, with urinary seaweed metabolites excretion less than 0.5 448 
m moles, while 55% of the population (43/78) were medium excretors (0.5 and 2 m moles) and 449 
the remaining 20% of the population (16/78) were high excretors (>2 m moles) (Supplemental 450 
Table 5). Despite exploration using PCA or HCA, the plasma metabolome did not allow a clear 451 
differentiation between participants in either treatment phase (data not shown). As a result, it 452 
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was not possible to define exposure biomarkers in plasma samples across all the participants 453 
(n=78).  454 
 455 
DISCUSSION 456 
The association of seaweed consumption with reduced CVD risk factor has been tested 457 
largely within in vitro or animal models, with only limited human data allowing substantiation 458 
of the proposed beneficial properties of seaweeds (12, 13, 34). The work reported in this paper 459 
represents the first comprehensive study of the in vivo bioactivity and bioavailability of 460 
seaweed (poly)phenolics on biomarkers of inflammation and oxidative stress in overweight 461 
and obese individuals. Participant retention rates were high (98%) and self-reported SPE 462 
capsule intake (97%) indicated that the intervention was implemented successfully in this 463 
group of participants. There was, however, no significant difference between the intervention 464 
(SPE capsule) and control (placebo capsule) phases for markers of oxidative stress, antioxidant 465 
status or inflammation in the population as a whole (n=78). Stratifying for BMI however 466 
revealed a significant albeit modest decrease in DNA damage in the obese population (n=36). 467 
This is consistent with Park et al. (35) who tested the natural microalgal carotenoid astaxanthin, 468 
in 14 healthy females (2 mg extract/d for 8 weeks) and showed a significant reduction in the 469 
oxidative damage plasma marker 8-hydroxy-2’-deoxyguanosine. Obese individuals are 470 
associated with increased basal DNA damage, higher oxidant status and increased oxidative 471 
damage to macromolecules as a group and are thus at higher risk of chronic disease (36-39). In 472 
the current work, an overweight/obese population (age 30-65 years, BMI >25 kg/m2) 473 
supplementation with seaweed (poly)phenolics significantly reduced basal levels of 474 
lymphocyte DNA damage (by 23%) but only in the obese sub-population (n=36). These two 475 
seaweed-extract interventions are consistent with data from in vitro studies which demonstrated 476 
anti-genotoxic activity for seaweed extracts on a range of cell lines (40,41), including the SPE 477 
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extract used in our study (15). The biological mechanism underpinning the observed reduction 478 
in DNA damage in the obese group could not be determined from our data, however the 479 
activation of the cytoprotective Nrf2/ARE pathway may be involved, as seaweed (poly)phenols 480 
such as eckol are anti-genotoxic (42) and can activate Nrf2-mediated HO-1 induction (43,44) 481 
consistent with effects observed for (poly)phenols from terrestrial sources (45,46). We 482 
observed a 28% decrease in CRP levels, as a marker of inflammation, in response to seaweed 483 
extract consumption however this change was not significant, in contrast to the observations 484 
of Park et al. (35). However, a study investigating the effect of consuming Palmaria palmata 485 
(5 g/day) incorporated into bread found that it significantly increased CRP by 16%, suggesting 486 
that P. palmata stimulates inflammation rather than reducing it (47). Park et al. (35) reported 487 
that there was no difference in TNF and IL-2 concentrations, but plasma IFN-γand IL-6 488 
increased on week 8 in participants given 8mg astaxanthin. Within our study, we similarly 489 
observed no significant changes in IL-2 or TNF, nor did we see an alteration in IFN-γor IL-6. 490 
The seaweed extract tested did not affect immune function (cell mediated and humoral immune 491 
responses as tested by the cytokine markers) following supplementation.rather than reducing it 492 
(47). Park et al. (35) reported that there was no difference in TNF and IL-2 concentrations, but 493 
plasma IFN-γand IL-6 increased on week 8 in participants given 8mg astaxanthin. Within this 494 
study, we similarly observed no significant changes in IL-2 or TNF, nor did we see an alteration 495 
in IFN-γor IL-6. The seaweed extract tested did not affect immune function (cell mediated and 496 
humoral immune responses as tested by the cytokine markers) following supplementation.  497 
 498 
A comparison of metabolic profiles between urine and plasma samples of 78 individuals who 499 
consumed seaweed capsules has allowed evaluation of seaweed molecules potentially 500 
responsible for the modest beneficial effects observed in vivo as well as identifying biological 501 
markers linked to seaweed consumption. We determined differences in the urine metabolite 502 
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profiles between participants, and thus were able to stratify the individuals into groups that 503 
shared common excretion metabolite profiles both pre- and post- seaweed supplementation. 504 
Despite substantial inter-individual variation in the concentration of seaweed metabolites 505 
excreted in urine (0.001 to 4.140 m moles, the urinary profiles of these two groups were 506 
statistically different and we have been able to select the metabolites responsible for this 507 
discrimination as potential biomarkers of seaweed consumption (Table 5). Our comprehensive 508 
multivariate analysis of the metabolite profiles showed the expected person-to-person variation 509 
in the 0-24h urinary excretion of seaweed (poly)phenols, which could be attributed to 510 
differences in gut microbiota or living conditions amongst study participants. Nonetheless, we 511 
could group the 78 participants by ability to metabolize seaweed (poly)phenols. Group 1 512 
individuals were characterized by greater excretion of seaweed–derived metabolites such as 513 
pyrogallol/phloroglucinol sulfate, hydroxytrifurahol A-sulfate and dioxinodehydroeckol, while 514 
Group 2 individuals were characterized by excretion of C-O-C dimer of phloroglucinol-sulfate, 515 
C-O-C dimer of phloroglucinol, fucophloroethol-glucuronide, diphlorethol sulfates and 516 
dioxinodehydroeckol glucuronide. This inter-individual variation in absorption of seaweed 517 
polyphenols is consistent with profiles previously observed in the bioavailability of dietary 518 
(poly)phenols such as orange, cranberry and pomegranate juices (48-50). 519 
 520 
The seaweed phenolic metabolites and can be divided into (a) phase II sulphated and 521 
glucuronidated metabolites related to the targeted components described earlier by Corona et 522 
al. (20) (Supplemental Tables 1 & 2); arguably formed in the liver, and  (b) an extended list 523 
of unknown compounds which could be potential breakdown products or metabolites of the 524 
original seaweed (poly)phenols catabolised by colonic bacteria.  However, further investigation 525 
would be required to confirm the identity and origin of these unknown compounds.  We 526 
previously reported the poor absorption of the high molecular weight phlorotannins in the upper 527 
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gastrointestinal tract (20) likely results in them reaching the colon and becoming subject to 528 
microbial fermentation to lower molecular weight derivatives, as we have recently shown using 529 
an in vitro gut microbiota model (15). The urinary metabolite profiles of seaweed phenolics 530 
from the low and high excretors clearly indicated a high inter-individual variation in 531 
metabolism. It is possible that inter-individual variation in gut microbiota underlie these 532 
metabolic changes and were responsible for the observed differences (51-53). The study of 533 
seaweed polyphenol(s) bioavailability remains challenging due to the high range of molecular 534 
weight compounds present, and their characterisation is complicated further by the lack of 535 
commercially available standards. Other limitations of the present study include a relatively 536 
short-term intervention, and thus results cannot be extrapolated to long-term chronic 537 
consumption. In addition, study participants were mostly recruited from the University of 538 
Ulster staff and local residents and thus may not be representative of the general overweight 539 
population of Northern Ireland. While lymphocyte DNA damage (spontaneous DNA SBs) is 540 
considered appropriate for the substantiation of EFSA health claims in the context of protection 541 
against generic DNA damage, a lesion specific enzyme such as (ENDO III) would have been 542 
required for a claim related to oxidative DNA damage (54). With respect to the TOC assay it 543 
is based on the reaction of endogenous peroxides with hydrogen peroxide, using TMB as the 544 
chromogenic substrate, and provides a measure of total peroxide levels in plasma. While this 545 
assay lacks specificity in comparison to other measures of oxidative stress, the direct 546 
correlation between oxygen radicals and peroxides allows measurement and characterization 547 
of the oxidative status/oxidative stress in biological fluids. Moreover the test is characterized 548 
by linearity, good precision, and endpoint determination (55). Finally, the study population 549 
number may have been too small to yield significant results in intercellular cytokines. These 550 
factors should be considered for the design of future studies in this area. 551 
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In conclusion, this work represents the first comprehensive human study investigating 552 
bioavailability and metabolism of seaweed (poly)phenolics. Consumption of SPE decreased 553 
DNA damage–albeit to a modest extent–in obese individuals only, with no clear effects on 554 
clinical markers of inflammation. Untargeted analysis identified novel urinary biomarkers of 555 
seaweed consumption and highlighted a high degree of inter-person variation in the metabolism 556 
of seaweed phenolics. Future studies that address the ingestion of seaweed phenolics will need 557 
to consider and adjust for these parameters, and this work has highlighted the importance of 558 
establishing an individual’s capacity for metabolising (poly)phenols.  559 
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Table 1. Key components of phlorotannin rich basic seaweed extract, High Molecular Weight 
(HMW) seaweed extract fraction, and blend used for intervention seaweed polyphenolic 
extract capsules (SPE). 
Extract component 
Basic seaweed 
extract 
HMW seaweed 
extract fraction 
Blend  
(SPE capsule) 
mg/175mg of extract mg/50mg of extract mg/400mg capsule 
Phlorotannin 61.25 46.05 107.3 
Iodine  0.48 0.02 0.5 
Maltodextrin1 0 0 175 
Minerals 39.38 13 52.38 
Fucoxanthin 0 36.5 36.5 
Laminarin as glucose  10.68 1.75 12.43 
Fucoidan as fucose 0 <0.001 <0.001 
Mannitol  29.23 5.9 35.13 
Inorganic arsenic  <0.001 <0.001 <0.001 
Cadmium (LD 0.15mg/kg) <LD  <LD  <LD  
Mercury (LD 0.016mg/kg) <LD  <LD  <LD  
Lead (LD 1.1mg/kg) <LD  <LD  <0.001 
Tin (LD 1.7mg/kg) <LD  <LD  <LD  
1maltodextrin was added to the capsule formulation as an excipient. 
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Table 2. Baseline characteristics of the study population (n=80). 
 
 
 
 
 
 
 
 
 
No significant differences P>0.05, Paired T Test. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Placebo 
treatment phase 
(n=80) 
SPE        
treatment phase 
(n=80) 
Age (y) 42.8 ± 7.2 42.9 ± 7.1 
Gender (M/W) 20/20 19/21 
Height (m) 1.71 ± 0.08 1.72 ± 0.10 
Weight (kg) 88.9 ± 14.1 89.1 ± 17.3 
BMI (kg/m2) 30.3 ± 3.5 30.0 ± 4.4 
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Table 3. Habitual nutrient intake of subjects during intervention study 
Variable intake 
Placebo 
treatment 
phase 
(n=77)1 
SPE  
treatment 
phase 
(n=77) 
% 
Change2 
P 
value3 
Energy (kcal/d) 1949 ± 5904 2057 ± 684 5 0.110 
Protein (g/d) 79.4 ± 28.6 79.9 ± 25.3 0.5 0.782 
Carbohydrate (g/d) 220.6 ± 72.1 231.3 ± 84.2 5 0.278 
Total fat (g/d) 78.6 ± 26.5 85.2 ± 34.8 8 0.058 
Saturated fat (g/d) 29.0 ± 10.2 30.7 ± 15.3 6 0.417 
Monounsaturated fat (g/d) 24.4 ± 9.3 26.8 ± 12.4 9 0.112 
Polyunsaturated fat (g/d) 12.1 ± 5.4 13.5 ± 6.4 10 0.059 
Fibre (g/d)5 12.9 ± 6.2 13.3 ± 4.8 3 0.259 
Vitamin C (mg/d) 71.8 ± 50.5 69.4 ± 47.1 -3 0.909 
Vitamin E (mg/d) 7.17 ± 3.7 7.67 ± 4.0 7 0.279 
Folate (µg/d) 223.9 ± 98.3 228.2 ± 85.5 2 0.370 
Carotene (µg/d) 2821 ± 1900 2553 ± 1706 -11 0.185 
1S66 did not complete a food diary in either phase. 2 Calculated from SPE phase – Placebo 
phase. 3 Mean treatment group values were not significantly different between phases, P<0.05 
(Wilcoxin signed rank test). 4 Mean ± SD. 5Calculated using the Englyst method. 
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Table 4. Effects of seaweed polyphenol extract on lymphocyte DNA damage, CRP and blood lipids.  
Data is presented as treatment affects, calculated based on individual differences between pre- and post- values for both control and treatment 
phases for each subject. Paired T-tests were then carried out on the difference scores (post-treatment value minus pre-treatment values) between 
treatment (Seaweed phenolic extract capsule) and placebo control phase (maltodextrin). Significance level was set at P<0.05 (one-tailed T test). 
       
   Total 
(n=78)      
Overweight 
 (n=42)   
   
 
Obese 
 (n=36)     
Blood marker 
Average 
baseline 
value 
Placebo 
treatment 
effect 
SPE treatment 
effect 
P 
value 
Average 
baseline 
value 
Placebo 
treatment 
effect 
SPE 
treatment 
effect 
P value 
Average 
baseline 
value 
Placebo 
treatment 
effect 
SPE 
treatment 
effect 
P value 
                
DNA damage – 
basal   (% Tail) 6.72 ± 2.48 0.74 ± 2.86 -0.41 ±  3.13 0.350 6.59 ± 2.80 0.32 ± 2.14 0.57 ± 3.24 0.129 6.91 ± 2.00 1.81 ± 4.50 0.15 ± 2.93 0.044 
DNA damage - 
H2O2 (%Tail) 
34.2 ± 7.00 -1.56 ± 6.60 -2.03 ± 6.40 0.390 35.2 ± 7.11 0.13 ± 2.19 0.76 ± 1.66 0.062 32.8 ± 6.69 1.26 ± 2.09 0.54 ± 1.54 0.111 
CRP (mg/ml) 2.67 ± 3.9 0.01 ± 3.3 -0.83 ± 4.9 0.429 2.59 ± 4.69 0.00 ± 3.40 -1.32 ± 6.22 0.348 2.80 ± 2.56 -1.81 ± 11.82 0.72 ± 5.15 0.258 
Cholesterol 
(mmol/l) 5.20 ± 0.77 -0.06 ± 0.57 -0.10 ± 0.57 0.256 5.18 ± 0.82 0.01 ± 0.55 -0.53 ± 0.54 0.201 5.24 ± 0.73 -0.13 ± 0.58 -0.15 ± 0.60 0.419 
Triglycerides 
(mmol/l) 1.51 ± 0.94 0.01 ± 0.82 0.04 ± 0.96 0.385 1.34 ± 0.72 0.07 ± 0.79 -0.04 ± 0.48 0.278 1.75 ± 1.15 -0.06 ± 0.85 -0.02 ± 1.34 0.497 
HDL (mmol/l) 1.37 ± 0.32 -0.01 ± 0.15 0.03 ± 0.15 0.187 1.46 ± 0.31 0.01 ± 0.16 -0.03 ± 0.15 0.150 1.25 ± 0.32 -0.04 ± 0.11 -0.04 ± 0.14 0.446 
LDL (mmol/l) 3.16 ± 0.1 -0.08 ± 0.5 -0.06 ± 0.50 0.478 3.13 ± 0.69 -0.07 ± 0.57 0.01 ± 0.45 0.383 3.20 ± 0.67 -0.09 ± 0.56 -0.13 ± 0.56 0.412 
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Table 5. Phlorotannins metabolites tentatively identified in human urine samples from Group 1 (70 subjects) and Group 2 (8 subjects) after 
seaweed capsule consumption. 
ID VIP value Rt (min) Experimental Molecular Weight Predicted Formula Metabolite putative identification Ratio1  
Group 1 (72 subjects) 
652 2.06 25.6 205.9881 C6H6O6S Pyrogallol/phloroglucinol sulfate 1.5  
800 2.28 25.8 205.9881 C6H6O6S Pyrogallol/phloroglucinol sulfate 1.2  
1472 3.86 24.9 205.9881 C6H6O6S Pyrogallol/phloroglucinol sulfate 1.1  
1352 4.26 25.6 486.1727 C22H30O12 Hydroxytrifuhaol A-glucuronide 2.0  
1453 3.83 25.4 486.1727 C22H30O12 Hydroxytrifuhaol A-glucuronide 1.9  
1458 4.23 25.3 486.1727 C22H30O12 Hydroxytrifuhaol A-glucuronide 2.2  
1483 4.39 25.3 486.1727 C22H30O12 Hydroxytrifuhaol A-glucuronide 2.2  
1917 2.11 31.4 544.2881 C27H44O11 Dioxinodehydroeckol glucuronide 1.1  
 
Group 2 (8 subjects) 
293 2.08 9.5 327.0951 C12H8O9S C-O-C dimer of phloroglucinol-sulfate 1.2  
702 2.20 24.1 248.0315 C12H8O6 C-O-C dimer of phloroglucinol 1.2  
853 2.08 27.8 797.3186 C45H49O13 Fucophloroethol glucuronide 1.1  
1293 2.28 34.2 330.1675 C12H10O9S Diphlorethol sulfate 1.9  
1356 2.31 34.1 330.1675 C12H10O9S Diphlorethol sulfate 1.7  
1633 2.07 35.1 544.2152 C27H44O11 Dioxinodehydroeckol glucuronide 1.2  
 
ID, identification number. VIP (variable influence in projection) is a variable that summarizes the importance of X variables to the OPLS-DA 
model. Variables with values > 2 were the most influential in the model.  All predicted formula derived with < 5 ppm mass accuracy data.  
1Ratio: seaweed capsule consumption/placebo consumption. 
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FIGURE 1. CONSORT DIAGRAM. Progress of participants through the intervention study. 
FIGURE 2. Comparison of the effects of SPE supplementation phase () with that of a placebo 
phase (•) on total oxidative capacity (TOC) in the total study population (n=78), in overweight 
(n=42), and in obese (n=36). All values were measured in duplicate expressed as mean ± SD. 
TOC is represented as the mean of the individual difference values (after – before 
supplementation) in the SPE and placebo treatment phases. 
 
FIGURE 3. Comparison of the effects of SPE supplementation phase () with that of a placebo 
phase () on cytokine levels in the total study population (n=78), in overweight (n=42), and 
in obese (n=36). All values were measured in duplicate expressed as mean ± SD. Cytokines 
were measured as the mean of the individual difference value (after – before supplementation) 
in the SPE and placebo treatment phases. Change in mean treatment group values were not 
significantly different between treatment phases, P>0.05 (Paired T Test; one-tailed test). 
M.F.I.; Mean Fluorescence Intensity. 
FIGURE 4. Principal Component Analysis (PCA) (A) and Hierachical Cluster Analysis 
Cluster (HCA) (B) of urinary profiles before (♦) and after (■) seaweed consumption by 80 
participants. The HCA was calculated based on Eucledian distances and the Ward hierachical 
agglomerative method. The PC explained 23.14% of the total variance (PC-1 14.8% and PC-2 
8.34 %). 
FIGURE 5 A) OPLS-DA scores and B) loadings of the urine samples belong to group of 
participants 1 (70 participants). C) OPLS-DA scores and D) loading of urine samples belong 
to group of participants 2 (8 participants) before (♦) and after (■) seaweed ingestion. (Circles 
shown in the graph represent a confidence of 95%). LV1: latent variable 1; LV 2: latent variable 
2. The cut off VIP value selected to be 2. For VIP scores identification see Table 5 and 
Supplemental Table 1. 
= 
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Analysis of the SPE capsule by NP-HPLC and LC-MS analysis ( as reported in Corona et al  Br J Nutr. 2016 Apr 
14;115(7):1240-53.) 
NP-HPLC analysis:  The phlorotannins in the food-grade SPE used to produce the capsule were analyzed by normal 
phase HPLC analysis as previously described (Corona G et al, BJN, 2016) using an HPLC 1100 series equipped with  
LiChrospher Si60-5 column (250 mm × 4.0 mm ID, 5 μm particle size from HICHROM (LISP60-5-250AF), fitted with a 
guard column LiChrospher Si60-5 from HICHROM (LISP60-5-10C5). The mobile phase contained A: 82 % 
dichloromethane + 2 % methanol + 2 % acetic acid in water and B: 96 % methanol + 2 % acetic acid in water and was 
pumped through the column at 1 ml/min. 10 µl of samples were injected and analyzed by the gradient program which 
were (min/%B): 0/0, 30/17.6,45/30.7, 50/87.8, 60/87.8, 80/0, 105/0 for detection of all compounds. The compounds 
were detected at a wavelength of 268 nm. All data were analyzed by ChemStation software. The phloroglucinol standard 
was injected at 0.1-100 µg/ml and phlorotannins in the capsules were analysed as phloroglucinol equivalents. 
 
LC-MS analysis: LC-MS analysis was conducted to analyse the food grade seaweed capsule as previously described 
(Corona G et al, BJN, 2016), and was carried out in the negative ion mode using LC-MS/MS utilizing electrospray 
ionisation (ESI).  Characterization was achieved using LC-MS/MS utilizing electrospray ionisation (ESI).  This consisted 
of an Agilent 1200 HPLC system equipped with a binary pump, degasser, auto-sampler, thermostat, column heater, 
photodiode array detector and an Agilent 1100 Series LC/MSD Mass Trap Spectrometer.  Separation of samples was 
achieved using a Zorbax SB C18 column (2.1 x 100 mm; 1.8 µm) (Agilent) and HPLC conditions were as follows: 
injection volume: 1 µL; column temperature: 25 °C; binary mobile system: (A) 0.1 % aqueous formic acid and (B) 0.1 % 
of formic acid in acetonitrile; flow rate: 0.2 mL/min.  A series of linear gradients were used for separation (min/%B): 
0/10, 3/10, 15/40, 40/70, 50/70, 65/10. Mass spectrometry was performed in the negative ion mode (scan range, m/z 
100-1000 Da; source temperature, 350 °C). All solvents used were LC-MS grade. 
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The SPE (supplemental figure 1) comprised a wide range of molecular weights (20-70 min), with abundance of very 
high molecular weight phlorotannins eluting at later retention time (50-70min) in our Normal-Phase method.  Using a 
RP-HPLC separation method coupled to ESI-MS analysis in negative ion mode (supplemental figure 3) we were able 
to identify some phlorotannin oligomers such as hydroxytrifuhalol A, tetrafucol, fucodiphlorethol, C-O-C dimmer of 
phloroglucinol, 7-hydroxyeckol, diphloretol and difucol.   
 
Supplemental Figure 1 . Chromatographic separation of phlorotannins contained in the seaweed extract by Normal-
Phase HPLC with diode array detection (268nm). 
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Supplemental figure 2. Characterisation of phlorotannins in the seaweed extract. A: Structures of phlorotannins 
identified in the seaweed extract: B: Phlorotannins in the seaweed extracts identified by LC-MS analysis in negative ion 
mode 
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Extraction /Analysis of Plasma and Urine samples by HPLC DAD. 
The HPLC-PDA described below has been removed from the original data due to the limitation of the HPLC DAD 
approach applied and replaced by analysis as decribed in paper. The data is now only available in supplemental 
information for context with existing papers on this topic using the same seaweed extract (SPE) . 
1) Corona G, Ji Y, Anegboonlap P, Hotchkiss S, Gill C, Yaqoob P, Spencer JP, Rowland I.Gastrointestinal modifications and bioavailability 
of brown seaweed phlorotannins and effects on inflammatory markers. Br J Nutr. 2016 Apr 14;115(7):1240-53  
2).Corona G, Coman MM, Guo Y, Hotchkiss S, Gill C, Yaqoob P, Spencer JP, Rowland I.Effect of simulated gastrointestinal digestion and 
fermentation on polyphenolic content and bioactivity of brown seaweed phlorotannin-rich extracts. Mol Nutr Food Res. 2017 Nov;61(11). 
doi: 10.1002/mnfr.201700223. Epub 2017 Aug 29 
 
Extraction of (poly)phenols from urine and blood samples for HPLC DAD 
Urine samples were prepared as follows: 10 µl of internal standard solution (resorcinol 200 µg/ml) were added to 
250 µl urine. Samples were analysed with and without enzymatic treatment (37°C, 40 min), in the presence of 1500 IU 
of β­glucuronidase and 50 IU of sulfatases from Helix pomatia (Type H-1). 1 ml of  methanol acidified with 0.5% acetic 
acid was added, samples were mixed and centrifuged for 15 min at 16,100 x g at 4°C, supernatants were transferred 
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to a new tube and dried on a speedvac. Dried samples were resuspended in 125 µl of mobile phase, completely 
dissolved, centrifuged and transferred to vials for HPLC-DAD.  
Plasma samples were prepared as follows: 10 µl of internal standard solution (resorcinol 200 µg/ml) were added to 
450 µl of plasma, then 50 µl of 1.2 M acetic acid were added and samples were mixed. Samples were analysed with 
and without enzymatic treatment (37°C, 40 min) in the presence of 1500 IU of β­glucuronidase and 50 IU of sulfatases 
from H. pomatia (Type H-1). 1 ml of 100% methanol acidified with 0.5% acetic acid was added and samples were 
centrifuged for 15 min at 16,100 x g at 4°C and supernatants were collected. This step was repeated 3 times, the last 
occasion with 50% methanol acidified with 0.5% acetic acid, and the supernatants were dried using a speedvac. The 
pellets were dissolved with 125 µl of mobile phase and transferred to vials for HPLC analysis. 
 
Analysis of seaweed phenolics in blood and urine by HPLC-DAD analysis  
Sample analysis was carried out with a Hewlett-Packard 1100 series liquid chromatography system (Hewlett-
Packard, Palo Alto, CA) equipped with a diode array detector (HP Chem Station Software system). Samples were 
analysed by reverse-phase HPLC using a Nova-Pak C18 column (4.6 x 250 mm) with 4µm particle size. The 
temperature of the column was maintained at 30ºC. The mobile phases consisted of a mixture of aqueous methanol 
5% in 0.1% hydrochloric acid 5 M (A) and a mixture of aqueous acetonitrile 50 in 0.1% hydrochloric acid 5 M (B) and 
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were pumped through the column at 0.7 ml/min. The following gradient system was used (min/% B): 0/5, 5/5, 40/50, 
55/100, 59,9/100, 60/5, with 10 min post-run for both compound and metabolite detections. The eluent was monitored 
by photodiode array detection at 280 nm and spectra of products obtained over the 200–600 nm range. Peaks were 
characterised by their retention time and spectra characteristics. A calibration curve of phloroglucinol was constructed 
using authentic standard (0.1–100 µg/ml) and in each case was found to be linear with correlation coefficients of 0.995. 
Metabolites were quantified as phloroglucinol equivalents. 
 
HPLC-DAD analysis of the urine (Supplmental Table 2) and plasma (Supplmental Table 3) samples, with and without 
glucuronidase/sulfatase treatment, showed the presence of a variety of metabolites absent in the baselines (before the 
intervention) in both plasma and urine samples. Some metabolite peaks were present in samples with and without 
enzymatic treatment, and therefore could be assigned to un-conjugated metabolites. Some other metabolite peaks 
were present only in samples without enzymatic treatment or were only appearing in samples enzymatically treated, 
and were attributed to conjugated forms (glucuronides and/or sulfates) and their enzymatically released un-conjugated 
forms. There was substantial inter-individual variation in (poly)phenol s excreted by the participants. In 42 participants, 
no (poly)phenol s were detected in urine and in the remainder (n=36) the amounts excreted ranged from 0.5 to 11.8 
mg/day (mean 8.2 ± 12.1 mg/d). Similarly, there was a large variation in plasma concentrations (42.1 ± 117.0 µg/ml), 
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with only 14 participants having detectable (poly)phenol s in their plasma, seven of which had no (poly)phenol s detected 
in their urine samples, in accordance with what was observed after acute consumption. It is worth clarifying that, despite 
inter-individual variability in polyphenols metabolism being common for many polyphenol classes, in the present case 
the observed variability could partially be the result of the methodological limitations with the HPLC-DAD analysis. 
 
Supplemental Table 1 
 
RP-HPLC analysis of seaweed metabolites in urine samples. Metabolites were detected in 36 out of 78 participants. 
RT (min) Metabolite 
Mean 
(mg) 
Stdev 
Volunteers 
(n) 
Enz 
(-) 
Enz 
(+) 
 
11.9 UM1 11.82 14.14 4 yes yes 
 
12.8 UM2 3.63 3.03 2 yes yes 
 
13.1 UM3 6.87 5.01 6 yes yes 
 
16.3 UM4 3.31 0.03 2 yes yes 
 
18.6 UM5 3.66 2.07 4 yes no 
 
21.7 UM6 6.17 3.16 4 yes yes 
 
24.5 UM7 3.46 2.02 4 no yes 
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25.2 UM8 0.47 0.26 2 yes no 
 
25.9 UM9 2.26 1.18 3 yes no 
 
28.8 UM10 0.79 0.53 2 no yes 
 
35.0 UM11 1.57 0.95 3 yes yes 
 
36.4 UM12 1.02 0.49 4 yes yes 
 
39.5 UM13 1.18 1.02 4 yes yes 
 
41.5 UM14 0.95 0.92 4 no yes 
 
44.2 UM15 0.92 0.74 6 no yes 
 
48.0 UM16 2.38 2.14 4 yes no 
 
49.6 UM17 5.42 5.23 5 no yes 
 
53.8 UM18 0.90 1.17 3 no yes 
 
  Group Mean  Total 8.16 12.10 36     
 
Phenolics in urine were quantified as phloroglucinol equivalents using HPLC and 
expressed as mg/d in urine. Note; the row “Group Mean Total ” represents the average of the 
sum (total excretion) of metabolites calculated for each individual volunteer. 
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Supplemental Table 2 
RP-HPLC analysis of seaweed metabolites in plasma samples.  Metabolites were detected in 14 out of 78 participants. 
RT (min) Metabolite 
Mean 
(µg/ml) 
Stdev 
Volunteers 
(n) 
Enz 
(-) 
Enz 
(+) 
 
8.5 PM1 148.12 91.12 2 no yes 
 
9.1 PM2 0.75 0.31 2 yes no 
 
11.0 PM3 23.71 12.69 2 yes no 
 
14.9 PM4 110.85 139.63 2 yes no 
 
31.0 PM5 2.56 1.54 3 yes no 
 
37.3 PM6 1.55 0.69 2 yes yes 
 
43.2 PM7 1.34 0.21 2 no yes 
 
45.3 PM8 0.64 0.18 2 no yes 
 
48.0 PM9 0.78 0.16 3 yes no 
 
58.7 PM10 2.62 0.56 2 yes yes 
 
  Group Mean Total 42.08 117.06 14     
 
Phenolics in plasma were quantified as phloroglucinol equivalents using HPLC and expressed as µg/ml in plasma. 
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Note; the row “Group Mean Total ” represents the average of the sum (total excretion) of metabolites calculated for each 
individual volunteer. 
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Supplemental Table 3. List of urine metabolites correlated with the chronic intake of seaweed capsules 
in group 1 formed by 70 participants. 
ID VIP value 
Experimental Molecular 
Weight Metabolite tentative identification 
41 5.8 332.18323 Unknown 
67 6.0 332.18323 Unknown 
165 5.2 182.99788 Saccharin 
292 5.0 182.99797 Saccharin 
298 5.1 176.06742 3-hydroxy-2-methoxyglutarate/glycerol-1,2-diacetate/3-isopropylmalate/2,3-dimethyl-3-hydroxyglutaric acid/2-isopropylmalic acid 
328 5.6 693.32784 Unknown 
372 5.1 182.9979 Saccharin 
416 4.9 182.99769 Saccharin 
457 4.6 234.01896 Ajoene/4-(2,2´-bithiophen-5-yl)-3-butyn-1-ol 
464 5.8 183.0885 Epinephrine/tretraydrohippuric acid/normetanephrine 
500 5.4 188.10399 Azelaic acid/butyl ethyl malonate/entre otros 
505 4.9 188.10391 Azelaic acid/butyl ethyl malonate/entre otros 
556 5.3 183.08848 Epinephrine/tretraydrohippuric acid/normetanephrine 
557 4.5 188.10397 Azelaic acid/butyl ethyl malonate/entre otros 
602 4.5 174.9926 Unknown 
650 6.6 382.16221 Ibuprofen glucuronide/cyclocalopin B 
652 3.8 205.98811 Pyrogallol-O-sulfate 
800 4.2 205.98816 Pyrogallol-O-sulfate 
801 5.2 182.99757 Saccharin 
847 3.3 350.1569 Eremopetasin sulfoxide 
940 4.2 692.32582 Pisumoside B 
956 5.3 372.10485 Dihydroferulic acid-4-O-glucuronide 
981 3.6 440.16758 Unknown 
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1025 4.0 351.09499 Indole-3-acetic-acid-O-glucuronide 
1106 5.8 150.01492 Tartalic acid/2,3-dihydroxybutanedioic acid/2-2-trienylfuran 
1130 3.7 440.16786 Unknown 
1155 3.9 440.16724 Unknown 
1213 5.0 542.27235 Cortolone-3-glucuronide 
1217 4.3 134.05685 2,3-dihydroxyvaleric acid/deoxyribose/dihydroxy-isovalerate/glycerol acetate 
1248 5.2 150.0146 Tartalic acid/2,3-dihydroxybutanedioic acid/2-2-trienylfuran 
1262 4.4 134.05696 2,3-dihydroxyvaleric acid/deoxyribose/dihydroxy-isovalerate/glycerol acetate 
1269 4.6 134.05687 2,3-dihydroxyvaleric acid/deoxyribose/dihydroxy-isovalerate/glycerol acetate 
1303 4.5 134.05689 2,3-dihydroxyvaleric acid/deoxyribose/dihydroxy-isovalerate/glycerol acetate 
1306 4.2 440.16771 Unknown 
1315 6.1 150.01506 Tartalic acid/2,3-dihydroxybutanedioic acid/2-2-trienylfuran 
1352 4.3 486.17277 Hydroxytrifuhaol A-glucuronide 
1408 4.3 810.29457 Unknown 
1429 4.5 356.11012 Hydroxy-methoxycinnamoyl-b-glucose/1-O-feruloylglucose/veranisatin B 
1453 3.8 486.17314 Hydroxytrifuhaol A-glucuronide 
1458 4.2 486.1734 Hydroxytrifuhaol A-glucuronide 
1472 3.9 205.98794 Pyrogallol-O-sulfate 
1483 4.4 486.17327 Hydroxytrifuhaol A-glucuronide 
1493 5.0 310.97636 Unknown 
1544 4.7 824.274 Unknown 
1648 5.3 233.03502 Dopamine sulfate 
1665 4.8 435.18873 Unknown 
1679 4.7 219.08849 
N-deschlorobenzoyl indomethacin/alpha-methoxy-1-H-indole-3-propanoic 
acid/nigellimine N-oxide/alpha-hydroxy-1H-indole-3-propanoic acid 
1693 5.4 251.0786 
N-carboxyacetyl-D-phenylalanine/N-phenylacetylaspartic acid/4-hydroxy-3-methoxy-
cinnamoylglycine 
1711 4.8 233.0349 Dopamine sulfate 
1715 4.6 181.07286 Tyrosine 
1725 4.2 298.10513 2-Phenylethanol glucuronide 
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1727 5.2 251.07833 
N-carboxyacetyl-D-phenylalanine/N-phenylacetylaspartic acid/4-hydroxy-3-methoxy-
cinnamoylglycine 
1737 5.0 219.0888 
N-deschlorobenzoyl indomethacin/alpha-methoxy-1-H-indole-3-propanoic 
acid/nigellimine N-oxide/alpha-hydroxy-1H-indole-3-propanoic acid 
1751 5.3 414.15204 Ptelatoside A 
1778 5.1 251.0785 
N-carboxyacetyl-D-phenylalanine/N-phenylacetylaspartic acid/4-hydroxy-3-methoxy-
cinnamoylglycine 
1799 5.4 842.39386 Unknown 
1806 3.5 338.947 Unknown 
1828 6.1 364.17303 Unknown 
1877 5.2 842.39393 Unknown 
1917 5.0 544.28816 Dioxinodehydroeckol glucuronide 
1924 4.7 360.1411 
Dimethoxyphenyl-ethanediol O-glucoside/2-(4-hydroxy-3,5-dimethoxyphenyl)ethanol 
4´-glucoside/ deoxyloganic acid 
1935 4.7 223.11987 Cerulenin 
1945 4.9 251.0785 
N-carboxyacetyl-D-phenylalanine/N-phenylacetylaspartic acid/4-hydroxy-3-methoxy-
cinnamoylglycine 
1948 4.2 218.02395 tyrosol-sulfate/diphenyl disulfide 
1953 4.1 378.05751 Unknown 
1961 4.9 400.1728 Corchoionoside B 
1970 4.7 223.11986 Cerulenin 
1995 5.1 372.10472 Dihydroferulic acid-4-O-glucuronide 
2038 5.3 360.14121 
Dimethoxyphenyl-ethanediol O-glucoside/2-(4-hydroxy-3,5-dimethoxyphenyl)ethanol 
4´-glucoside/ deoxyloganic acid 
2040 5.5 526.27719 Unknown 
2059 5.4 504.19905 Myricatomentoside I/chlorhexidine 
2063 4.4 398.10594 Methyl 3,4-dihydroxy-5-prenylbenzoate-3-glucoside 
2072 4.4 372.10487 Dihydroferulic acid-4-O-glucuronide 
2080 5.4 324.06294 Sterigmatocystin/greviline A 
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2081 4.6 251.07794 
N-carboxyacetyl-D-phenylalanine/N-phenylacetylaspartic acid/4-hydroxy-3-methoxy-
cinnamoylglycine 
2185 4.8 280.05956 Unknown 
2186 4.8 280.05942 Unknown 
2188 4.8 240.12161 Anserine/homocarnosine/balenine 
2194 5.4 213.00886 Indoxyl sulfate/carmustine 
 
 All predicted formula derived with < 5 ppm mass accuracy data. VIP (variable influence in projection) is a variable that 
summarizes the importance of X variables to the OPLS-DA model. Variables with VIP values > 2 were the main 
contributors in the model. ID, identification number. Metabolites were searcher against two data based, (Metlin 
database; http://metlin.scripps.edu/ and HMDB: http://hmdb.ca). Searching metabolites do not include heavy metal and 
halogens.  
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Supplemental Table 4. List of plasma metabolites correlated with the chronic intake of seaweed capsules. 
ID VIP value 
Experimental Molecular 
weight Tentative identification 
1315 2.1 150.01506 Tartalic acid/2,3-dihydroxybutanedioic acid/2-2-trienylfuran 
1450 3.1 188.01341 p-cresol sulfate 
246 2.2 195.95296 Unknown 
114 2.4 195.953 Unknown 
111 2.3 195.95304 Unknown 
977 2.3 208.00368 Unknown 
2066 2.1 210.03589 Galactaric acid/glucaric acid 
797 2.0 213.00848 Indoxyl sulfate/carmustine 
1948 2.0 218.02395 tyrosol-sulfate/diphenyl disulfide 
1711 2.1 233.0349 Dopamine sulfate 
1648 2.3 233.03502 Dopamine sulfate 
2097 2.2 233.03511 Dopamine sulfate 
587 2.0 236.10413 
4-hydroxy-3-methoxy-5-(3-methylbut-2-en-1-yl)benzoic 
acid/carboxy-ibuprofen/ethyl vanillin isobutyrate 
496 2.0 236.10422 
4-hydroxy-3-methoxy-5-(3-methylbut-2-en-1-yl)benzoic 
acid/carboxy-ibuprofen/ethyl vanillin isobutyrate 
892 2.1 246.0189 Unknown 
2138 2.7 278.03987 Unknown 
2186 3.2 280.05942 Unknown 
2185 3.3 280.05956 Unknown 
706 2.5 293.9301 Unknown 
622 2.1 293.9301 Unknown 
2119 3.2 324.12077 Unknown 
2035 3.0 324.12114 Unknown 
588 2.1 326.13624 
4-(4´-hydroxyphenyl)2-butanone glucoside/ citrusin C/1-
methoxy-3-(4-hydroxyphenyl)-2E-propenal 4´-glucoside 
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654 2.4 326.13646 
4-(4´-hydroxyphenyl)2-butanone glucoside/ citrusin C/1-
methoxy-3-(4-hydroxyphenyl)-2E-propenal 4´-glucoside 
1293 2.3 330.16753 Diphlorethol sulfate 
1356 2.3 330.16795 Diphlorethol sulfate 
2163 2.0 336.0294 Unknown 
2013 2.0 336.02953 Unknown 
1958 2.2 347.14012 Unknown 
2068 2.5 358.08919 Dihydrocaffeic acid -O-glucuronide 
519 2.6 360.14168 
Dimethoxyphenyl-ethanediol O-glucoside/2-(4-hydroxy-3,5-
dimethoxyphenyl)ethanol 4´-glucoside/ deoxyloganic acid 
430 2.2 360.14198 
Dimethoxyphenyl-ethanediol O-glucoside/2-(4-hydroxy-3,5-
dimethoxyphenyl)ethanol 4´-glucoside/ deoxyloganic acid 
1540 2.3 380.14656 Gibberellin A75/8-oxodiacetoxyscirpenol 
1357 2.0 382.16224 Ibuprofen glucuronide/cyclocalopin B 
381 2.4 398.15706 Methyl 3,4-dihydroxy-5-prenylbenzoate-3-glucoside 
364 2.0 398.15764 Methyl3,4-dihydroxy-5-prenylbenzoate-3-glucoside 
234 2.0 412.13594 Methylpicraquassioside A 
134 2.3 412.136 Methylpicraquassioside A 
214 2.0 412.13618 Methylpicraquassioside A 
154 2.0 412.13626 Methylpicraquassioside A 
159 2.2 412.13637 Methylpicraquassioside A 
164 2.2 412.13649 Methylpicraquassioside A 
1751 2.0 414.15204 Ptelatoside A 
2134 2.1 440.09245 
3,5-dihydroxyphenyl-1-O-(6-O-galloyl-beta-D-
glucopyranoside) 
1633 2.1 544.21522 Dioxinodehydroeckol glucuronide 
351 2.0 796.31532 Unknown 
853 2.1 797.31862 Fucophloroethols glucuronide 
1182 2.0 169.0363 2-furoylglycine/L-2-3,dihydrodipicolinate 
1627 2.4 174.08776 Suberic acid/ 2-propylglutaric acid 
753 2.1 174.99243 Unknown 
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1083 2.1 174.99252 Unknown 
602 2.8 174.9926 Unknown 
859 2.3 174.9926 Unknown 
1023 2.1 174.9926 Unknown 
769 2.0 174.99263 Unknown 
2094 2.3 189.00848 Lanthionine ketimine/2-aminophenol sulphate 
244 2.1 229.00336 Unknown 
702 2.0 248.0315 C-O-C dimer of phloroglucinol 
1918 2.8 259.99821 Caffeic acid 3-sulfate 
887 2.2 261.03016 Unknown 
1120 2.8 290.04494 4-hydroxy-5-(hydroxyphenyl)-valeric acid-sulfate 
1677 2.1 303.05847 Unknown 
1481 2.9 314.09898 2-hydroxyphenylacetic acid-O-glucuronide 
1993 2.1 314.09898 2-hydroxyphenylacetic acid-O-glucuronide 
293 2.1 327.09512 C-O-C dimer of phloroglucinol-sulfate 
839 2.1 328.09828 Difucol/diphlorethol glucuronide 
952 2.2 350.02393 Unknown 
847 2.0 350.1569 Eremopetasin sulfoxide 
1066 2.4 357.10545 
HMBOA-GLc (known as 2-O-glucosyl-7-methoxy-1,4-
benzoxazin-3-one 
625 2.2 357.10548 
HMBOA-GLc (known as 2-O-glucosyl-7-methoxy-1,4-
benzoxazin-3-one 
479 2.1 357.1056 
HMBOA-GLc (known as 2-O-glucosyl-7-methoxy-1,4-
benzoxazin-3-one 
626 2.4 357.10573 
HMBOA-GLc (known as 2-O-glucosyl-7-methoxy-1,4-
benzoxazin-3-one 
1966 2.0 358.08912 Dihydrocaffeic acid-O-glucuronide 
1620 2.1 359.06694 Unknown 
1351 2.3 362.15735 Unknown 
870 2.4 362.15748 Unknown 
1792 2.9 368.10989 3-O-feruloylquinic acid/O-caffeoyl-O-methylquinic acid 
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1758 2.4 370.08925 
Feruloyl C-glucuronide/isoferulic acid-3-O-glucuronide/5-
hydroxy-6-methoxycoumarin7-glucoside 
1683 2.0 370.08926 
Feruloyl C-glucuronide/isoferulic acid-3-O-glucuronide/5-
hydroxy-6-methoxycoumarin7-glucoside 
1788 2.3 370.08955 
Feruloyl C-glucuronide/isoferulic acid-3-O-glucuronide/5-
hydroxy-6-methoxycoumarin7-glucoside 
1682 2.9 372.10469 Dihydroferulic acid-4-O-glucuronide 
1757 2.8 372.10469 Dihydroferulic acid-4-O-glucuronide/veranisatin C 
1634 2.6 372.10469 Dihydroferulic acid-4-O-glucuronide 
1765 2.9 372.10475 Dihydroferulic acid-4-O-glucuronide 
1719 2.9 372.10491 Dihydroferulic acid-4-O-glucuronide 
1570 2.1 372.10499 Veranisatin C/dihydroferulic acid-glucuronide 
1776 2.2 380.16774 
3-Methyl-3-butenyl apiosyl-glucoside/prenyl arabinosyl-
glucoside/ecabet 
1496 2.8 384.05021 Unknown 
2017 3.0 384.12615 Unknown 
1512 2.0 388.17252 
hydroxypropyl-2-methoxyphenoxyl-1,3-propanediol 1 
xyloside/jasmonic acid derivative 
1941 2.1 388.17283 
hydroxypropyl-2-methoxyphenoxyl-1,3-propanediol 1 
xyloside/jasmonic acid derivative 
1638 2.7 388.17311 
hydroxypropyl-2-methoxyphenoxyl-1,3-propanediol 1 
xyloside/jasmonic acid derivative 
1330 2.7 410.04463 Unknown 
1768 2.8 410.0451 Unknown 
1341 2.4 446.09862 Unknown 
1551 2.3 446.09904 Unknown 
1664 2.0 496.23067 Glaucarubin 
1781 2.5 509.13896 trans-hydroxycyclohexyl glyburide (Benzenesulfonamides) 
 
All predicted formula derived with < 5 ppm mass accuracy data. VIP (variable influence in projection) is a variable that 
summarizes the importance of X variables to the OPLS-DA model. Variables with VIP values > 2 were the main 
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contributors in the model. ID, identification number. Metabolites were searcher against two data based, (Metlin 
database; http://metlin.scripps.edu/ and HMDB: http://hmdb.ca). Searching metabolites do not include heavy metal and 
halogens.  
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Supplemental Figure 3. OPLS-DA scores plots of the urine samples belong to group of participants 1 (70 volunteers-
red) and group of subject 2 (8 participants-green) before (A) and after (B) seaweed consumption. LV1: latent variable 
1; LV 2: latent variable 2.  
 
 
Supplemental table 5  Total ex         
Subject Id Pyrogallol/Phloroglucinol-sulfate
S58 0.000
S61 0.000
S76 0.000
S78 0.000
S60 0.000
S70 0.003
S79 0.000
S83 0.000
S64 0.015
S40 0.047
S27 0.057
S66  0.064
S25  0.040
S65 0.085
S30  0.040
S71 0.000
S10  0.070
S33 0.128
S03  0.085
S59  0.111
S74  0.098
S19  0.156
S43  0.176
S39  0.085
S75  0.065
S01  0.184
S15  0.130
S53 0.125
S41 0.209
S36 0.225
S49  0.327
S82  0.328
S04 0.312
S46 0.347
S57  0.407
S81  0.373
S54  0.232
S35 0.204
S67  0.235
S16  0.447
S05 0.060
S23 0.547
S17 0.508
S08  0.302
S52 0.477
S29  0.407
S56  0.513
S02 0.532
S18 0.635
S38 0.337
S34 0.377
S31  0.531
S21 0.417
S24 0.453
S55  0.596
S22  0.500
S11 0.514
S37  0.287
S48  0.604
S42 0.436
S44 0.846
S63 0.535
S06 0.601
S12  0.366
S13 0.317
S62  0.555
S14 0.640
S20  0.843
S72  0.772
S32 0.682
S73  0.711
S26  0.533
S77  1.089
S07  0.622
S09 0.867
S51 1.158
S47  0.731
S50 1.470
     xcretion of identifed seaweed polyphenols in urine (mMo  
Pyrogallol/Phloroglucinol-sulfate Pyrogallol/Phloroglucinol-sulfate
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.004 0.004
0.000 0.000
0.000 0.000
0.016 0.022
0.036 0.004
0.064 0.012
0.091 0.012
0.026 0.019
0.055 0.110
0.062 0.007
0.000 0.000
0.078 0.020
0.259 0.018
0.095 0.017
0.214 0.015
0.148 0.003
0.114 0.026
0.285 0.030
0.119 0.011
0.263 0.023
0.171 0.106
0.105 0.035
0.081 0.093
0.319 0.034
0.313 0.021
0.327 0.090
0.212 0.037
0.348 0.048
0.417 0.014
0.514 0.014
0.570 0.046
0.583 0.045
0.253 0.037
0.493 0.063
0.616 0.074
0.052 0.045
0.320 0.062
0.574 0.108
0.373 0.046
0.511 0.083
0.586 0.056
0.473 0.193
0.662 0.055
0.543 0.074
0.261 0.716
0.580 0.069
0.867 0.085
0.334 0.183
0.573 0.062
0.671 0.094
0.720 0.083
0.693 0.043
0.628 0.058
0.714 0.081
0.340 0.591
0.611 0.157
0.952 0.067
0.673 0.111
0.452 0.042
0.246 0.402
0.944 0.077
0.964 0.037
0.786 0.318
1.026 0.031
1.178 0.105
1.223 0.120
1.039 0.129
0.898 0.284
0.884 0.072
0.977 0.126
0.827 0.167
1.534 0.132
0.984 0.216
            oles) 
Participants
Hydroxytrifuhaol-A-glucuronide
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.029
0.034
0.023
0.062
0.017
0.068
0.000
0.090
0.019
0.094
0.063
0.076
0.073
0.031
0.117
0.093
0.069
0.146
0.156
0.105
0.105
0.076
0.095
0.112
0.095
0.074
0.062
0.123
0.206
0.149
0.064
0.331
0.127
0.070
0.217
0.142
0.120
0.060
0.110
0.065
0.042
0.195
0.041
0.202
0.171
0.103
0.142
0.188
0.216
0.120
0.130
0.089
0.120
0.180
0.375
0.382
0.162
0.165
0.081
0.127
0.086
0.086
0.287
0.078
0.323
0.249
0.181
0.117
0.378
Total mmoles excreted in urine
Hydroxytrifuhaol-A-glucuronide Hydroxytrifuhaol-A-glucuronide
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.027 0.028
0.030 0.031
0.025 0.028
0.055 0.039
0.022 0.025
0.066 0.064
0.000 0.000
0.080 0.082
0.016 0.015
0.083 0.084
0.050 0.043
0.069 0.069
0.061 0.061
0.032 0.032
0.113 0.106
0.082 0.085
0.063 0.063
0.133 0.133
0.133 0.142
0.088 0.087
0.091 0.086
0.068 0.069
0.097 0.097
0.095 0.101
0.084 0.083
0.070 0.067
0.054 0.056
0.121 0.109
0.199 0.187
0.141 0.135
0.062 0.058
0.299 0.301
0.151 0.115
0.066 0.064
0.193 0.193
0.117 0.102
0.129 0.129
0.115 0.134
0.097 0.093
0.104 0.107
0.081 0.103
0.167 0.153
0.045 0.048
0.193 0.185
0.166 0.155
0.102 0.094
0.126 0.129
0.177 0.165
0.242 0.196
0.117 0.109
0.134 0.126
0.080 0.081
0.098 0.109
0.159 0.163
0.318 0.341
0.335 0.347
0.172 0.147
0.147 0.150
0.076 0.074
0.122 0.116
0.096 0.102
0.080 0.078
0.250 0.229
0.089 0.088
0.286 0.293
0.221 0.226
0.164 0.164
0.108 0.107
0.411 0.343
(N=78)
Hydroxytrifuhaol-A-glucuronide Dioxinodehydroeckol-glucuronide
0.000 0.000
0.000 0.000
0.000 0.001
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.001
0.029 0.000
0.029 0.000
0.028 0.000
0.035 0.001
0.026 0.000
0.059 0.000
0.000 0.000
0.037 0.000
0.017 0.000
0.038 0.001
0.028 0.000
0.066 0.000
0.069 0.000
0.032 0.000
0.099 0.001
0.071 0.000
0.057 0.000
0.128 0.001
0.143 0.000
0.056 0.001
0.060 0.000
0.006 0.000
0.105 0.000
0.090 0.000
0.066 0.000
0.065 0.000
0.055 0.001
0.013 0.000
0.167 0.000
0.121 0.000
0.059 0.000
0.304 0.000
0.107 0.001
0.059 0.000
0.151 0.000
0.050 0.000
0.122 0.000
0.127 0.000
0.082 0.000
0.113 0.001
0.116 0.000
0.115 0.001
0.047 0.000
0.187 0.001
0.151 0.001
0.094 0.001
0.095 0.000
0.018 0.000
0.194 0.000
0.107 0.000
0.125 0.001
0.076 0.000
0.105 0.000
0.120 0.001
0.182 0.000
0.160 0.002
0.149 0.000
0.116 0.000
0.070 0.000
0.110 0.000
0.108 0.001
0.079 0.000
0.132 0.001
0.089 0.001
0.217 0.001
0.103 0.000
0.162 0.000
0.102 0.001
0.338 0.000
C-O-C dimer of phloroglucinol-sulfatC-O-C dimer of phloroglucinol
0.000 0.000
0.000 0.001
0.000 0.001
0.000 0.001
0.002 0.000
0.000 0.000
0.000 0.001
0.039 0.006
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.391 0.005
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
Fucophloroethol glucuronide Diphlorethol sulfate
0.000 0.000
0.000 0.000
0.000 0.001
0.000 0.001
0.000 0.002
0.000 0.000
0.000 0.009
0.000 0.001
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.004
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
0.000 0.000
Diphlorethol sulfate Total metabolites (mmoles) 
0.000 0.001
0.000 0.001
0.001 0.003
0.001 0.003
0.002 0.006
0.000 0.012
0.008 0.019
0.001 0.047
0.000 0.055
0.000 0.200
0.000 0.258
0.000 0.270
0.000 0.278
0.000 0.341
0.000 0.367
0.004 0.405
0.000 0.459
0.000 0.473
0.000 0.498
0.000 0.525
0.000 0.530
0.000 0.561
0.000 0.618
0.000 0.651
0.000 0.683
0.000 0.714
0.000 0.812
0.000 0.874
0.000 0.899
0.000 0.902
0.000 0.964
0.000 0.972
0.000 1.106
0.000 1.107
0.000 1.212
0.000 1.216
0.000 1.227
0.000 1.254
0.000 1.338
0.000 1.381
0.000 1.394
0.000 1.430
0.000 1.450
0.000 1.477
0.000 1.483
0.000 1.550
0.000 1.616
0.000 1.632
0.000 1.642
0.000 1.657
0.000 1.660
0.000 1.665
0.000 1.701
0.000 1.733
0.000 1.756
0.000 1.796
0.000 1.797
0.000 1.821
0.000 1.852
0.000 1.883
0.000 1.942
0.000 1.986
0.000 2.007
0.000 2.078
0.000 2.192
0.000 2.206
0.000 2.220
0.000 2.249
0.000 2.305
0.000 2.357
0.000 2.377
0.000 2.600
0.000 2.617
0.000 2.699
0.000 2.769
0.000 2.825
0.000 2.832
0.000 4.140
Mean 1.29
Sd 0.88
min 0.001
max 4.140
Low (<.5 mmole High>2mmole
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Low (<.5 mmole High>2mmole
19 16
Subject Id Total meta   Low (<.5 mmole =1 High>2mmole =2
S58 0.00 1.00
S61 0.00 1.00
S76 0.00 1.00
S78 0.00 1.00
S60 0.01 1.00
S70 0.01 1.00
S79 0.02 1.00
S83 0.05 1.00
S64 0.05 1.00
S40 0.20 1.00
S27 0.26 1.00
S66  0.27 1.00
S25  0.28 1.00
S65 0.34 1.00
S30  0.37 1.00
S71 0.40 1.00
S10  0.46 1.00
S33 0.47 1.00
S03  0.50 1.00
S59  0.53
S74  0.53
S19  0.56
S43  0.62
S39  0.65
S75  0.68
S01  0.71
S15  0.81
S53 0.87
S41 0.90
S36 0.90
S49  0.96
S82  0.97
S04 1.11
S46 1.11
S57  1.21
S81  1.22
S54  1.23
S35 1.25
S67  1.34
S16  1.38
S05 1.39
S23 1.43
S17 1.45
S08  1.48
S52 1.48
S29  1.55
S56  1.62
S02 1.63
S18 1.64
S38 1.66
S34 1.66
S31  1.67
S21 1.70
S24 1.73
S55  1.76
S22  1.80
S11 1.80
S37  1.82
S48  1.85
S42 1.88
S44 1.94
S63 1.99
S06 2.01 2.00
S12  2.08 2.00
S13 2.19 2.00
S62  2.21 2.00
S14 2.22 2.00
S20  2.25 2.00
S72  2.31 2.00
S32 2.36 2.00
S73  2.38 2.00
S26  2.60 2.00
S77  2.62 2.00
S07  2.70 2.00
S09 2.77 2.00
S51 2.82 2.00
S47  2.83 2.00
S50 4.14 2.00
